Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Aestus Therapeutics has entered into a multi-year R&D collaboration agreement with Eisai on novel therapeutics for the treatment of psychiatric disorders. The collaboration is expected to include pre-clinical validation of potential therapeutics leading to clinical proof-of-concept studies.
Subscribe to our email newsletter
Earlier, Aestus has identified several products to treat certain psychiatric disorders. Now in partnership with Eisai, Aestus is expected to use those products for potential subsequent development in clinical trials.
Tage Honore, co-founder and CEO of Aestus, said: “Aestus is delighted that this collaboration with Eisai combines our strengths in this work to develop novel therapies for people affected by psychiatric disorders.
“Eisai’s proven talent and expertise will enable us to move drug candidates through the clinical development process efficiently with the goal of bringing innovative new treatments to the market place.
“It is our hope that the products we discover through this collaboration will improve the quality of life for the millions of sufferers of psychiatric disorders and their families.”